nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Prednisone—psoriatic arthritis	0.308	0.5	CpDpCtD
Sulindac—osteoarthritis—Methylprednisolone—psoriatic arthritis	0.308	0.5	CpDpCtD
Sulindac—ALB—Auranofin—psoriatic arthritis	0.0844	0.292	CbGbCtD
Sulindac—PTGS2—Triamcinolone—psoriatic arthritis	0.0533	0.185	CbGbCtD
Sulindac—PTGS2—Betamethasone—psoriatic arthritis	0.0457	0.158	CbGbCtD
Sulindac—ALB—Prednisone—psoriatic arthritis	0.0269	0.0931	CbGbCtD
Sulindac—PTGS2—Dexamethasone—psoriatic arthritis	0.0266	0.0921	CbGbCtD
Sulindac—CYP1A1—Dexamethasone—psoriatic arthritis	0.0224	0.0778	CbGbCtD
Sulindac—SLC22A6—Methotrexate—psoriatic arthritis	0.0158	0.0548	CbGbCtD
Sulindac—ALB—Methotrexate—psoriatic arthritis	0.0135	0.0467	CbGbCtD
Sulindac—MAPK3—IL17 signaling pathway—TRAF3IP2—psoriatic arthritis	0.00103	0.128	CbGpPWpGaD
Sulindac—PTGDR2—tendon—psoriatic arthritis	0.000724	0.2	CbGeAlD
Sulindac—PTGS2—skeletal joint—psoriatic arthritis	0.00063	0.174	CbGeAlD
Sulindac—PTGS2—synovial membrane of synovial joint—psoriatic arthritis	0.000479	0.132	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.000436	0.159	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000429	0.156	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000429	0.156	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.000419	0.153	CbGdCrCtD
Sulindac—MAPK3—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.000398	0.0494	CbGpPWpGaD
Sulindac—AKR1B1—tendon—psoriatic arthritis	0.000385	0.106	CbGeAlD
Sulindac—MAPK3—skin of body—psoriatic arthritis	0.000366	0.101	CbGeAlD
Sulindac—MAPK3—IL17 signaling pathway—IL17A—psoriatic arthritis	0.000312	0.0387	CbGpPWpGaD
Sulindac—PPARD—tendon—psoriatic arthritis	0.000303	0.0835	CbGeAlD
Sulindac—MAPK3—tendon—psoriatic arthritis	0.000279	0.077	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000263	0.0957	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000259	0.0942	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000259	0.0942	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000253	0.0921	CbGdCrCtD
Sulindac—MAPK3—IL-1 signaling pathway—REL—psoriatic arthritis	0.000234	0.0291	CbGpPWpGaD
Sulindac—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000197	0.0245	CbGpPWpGaD
Sulindac—MAPK3—Leptin signaling pathway—REL—psoriatic arthritis	0.000183	0.0227	CbGpPWpGaD
Sulindac—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriatic arthritis	0.000182	0.0226	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—REL—psoriatic arthritis	0.000158	0.0196	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000157	0.0195	CbGpPWpGaD
Sulindac—MAPK3—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.000156	0.0194	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.000156	0.0193	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000155	0.0193	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.000148	0.0183	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000146	0.0182	CbGpPWpGaD
Sulindac—Syncope—Triamcinolone—psoriatic arthritis	0.000141	0.00174	CcSEcCtD
Sulindac—Vertigo—Methylprednisolone—psoriatic arthritis	0.000141	0.00174	CcSEcCtD
Sulindac—Syncope—Methylprednisolone—psoriatic arthritis	0.00014	0.00174	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000139	0.00172	CcSEcCtD
Sulindac—Oedema—Prednisolone—psoriatic arthritis	0.000139	0.00172	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—psoriatic arthritis	0.000139	0.00172	CcSEcCtD
Sulindac—Dysuria—Methotrexate—psoriatic arthritis	0.000139	0.00172	CcSEcCtD
Sulindac—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000138	0.00171	CcSEcCtD
Sulindac—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000138	0.0017	CcSEcCtD
Sulindac—MAPK3—IL-6 signaling pathway—CRP—psoriatic arthritis	0.000137	0.017	CbGpPWpGaD
Sulindac—Shock—Prednisolone—psoriatic arthritis	0.000137	0.00169	CcSEcCtD
Sulindac—Convulsion—Triamcinolone—psoriatic arthritis	0.000136	0.00168	CcSEcCtD
Sulindac—Tachycardia—Prednisolone—psoriatic arthritis	0.000136	0.00168	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.000136	0.00168	CcSEcCtD
Sulindac—Convulsion—Methylprednisolone—psoriatic arthritis	0.000136	0.00168	CcSEcCtD
Sulindac—Hypertension—Triamcinolone—psoriatic arthritis	0.000136	0.00168	CcSEcCtD
Sulindac—Hypertension—Methylprednisolone—psoriatic arthritis	0.000135	0.00167	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000135	0.00167	CcSEcCtD
Sulindac—Myalgia—Triamcinolone—psoriatic arthritis	0.000134	0.00165	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—psoriatic arthritis	0.000133	0.00165	CcSEcCtD
Sulindac—Myalgia—Methylprednisolone—psoriatic arthritis	0.000133	0.00165	CcSEcCtD
Sulindac—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000133	0.00165	CcSEcCtD
Sulindac—MAPK3—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000133	0.0165	CbGpPWpGaD
Sulindac—Depression—Methotrexate—psoriatic arthritis	0.000132	0.00164	CcSEcCtD
Sulindac—Flushing—Prednisone—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Discomfort—Triamcinolone—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Discomfort—Methylprednisolone—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000132	0.00163	CcSEcCtD
Sulindac—Renal failure—Methotrexate—psoriatic arthritis	0.00013	0.00161	CcSEcCtD
Sulindac—Angioedema—Dexamethasone—psoriatic arthritis	0.00013	0.00161	CcSEcCtD
Sulindac—Angioedema—Betamethasone—psoriatic arthritis	0.00013	0.00161	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—psoriatic arthritis	0.000129	0.0016	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000129	0.00159	CcSEcCtD
Sulindac—Malaise—Betamethasone—psoriatic arthritis	0.000128	0.00159	CcSEcCtD
Sulindac—Malaise—Dexamethasone—psoriatic arthritis	0.000128	0.00159	CcSEcCtD
Sulindac—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Oedema—Triamcinolone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Vertigo—Dexamethasone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Vertigo—Betamethasone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Syncope—Dexamethasone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Syncope—Betamethasone—psoriatic arthritis	0.000128	0.00158	CcSEcCtD
Sulindac—Arrhythmia—Prednisone—psoriatic arthritis	0.000127	0.00157	CcSEcCtD
Sulindac—Sweating—Methotrexate—psoriatic arthritis	0.000127	0.00157	CcSEcCtD
Sulindac—Haematuria—Methotrexate—psoriatic arthritis	0.000126	0.00156	CcSEcCtD
Sulindac—Shock—Triamcinolone—psoriatic arthritis	0.000126	0.00156	CcSEcCtD
Sulindac—Insomnia—Prednisolone—psoriatic arthritis	0.000126	0.00156	CcSEcCtD
Sulindac—Alopecia—Prednisone—psoriatic arthritis	0.000126	0.00156	CcSEcCtD
Sulindac—Shock—Methylprednisolone—psoriatic arthritis	0.000126	0.00155	CcSEcCtD
Sulindac—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000125	0.00155	CcSEcCtD
Sulindac—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000125	0.00155	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—psoriatic arthritis	0.000125	0.00155	CcSEcCtD
Sulindac—Paraesthesia—Prednisolone—psoriatic arthritis	0.000125	0.00155	CcSEcCtD
Sulindac—Tachycardia—Triamcinolone—psoriatic arthritis	0.000125	0.00155	CcSEcCtD
Sulindac—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000125	0.00154	CcSEcCtD
Sulindac—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000124	0.00153	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000124	0.00153	CcSEcCtD
Sulindac—MAPK3—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000124	0.0154	CbGpPWpGaD
Sulindac—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000124	0.00153	CcSEcCtD
Sulindac—Convulsion—Betamethasone—psoriatic arthritis	0.000123	0.00153	CcSEcCtD
Sulindac—Convulsion—Dexamethasone—psoriatic arthritis	0.000123	0.00153	CcSEcCtD
Sulindac—Hypertension—Betamethasone—psoriatic arthritis	0.000123	0.00152	CcSEcCtD
Sulindac—Hypertension—Dexamethasone—psoriatic arthritis	0.000123	0.00152	CcSEcCtD
Sulindac—Myalgia—Betamethasone—psoriatic arthritis	0.000121	0.0015	CcSEcCtD
Sulindac—Myalgia—Dexamethasone—psoriatic arthritis	0.000121	0.0015	CcSEcCtD
Sulindac—Discomfort—Dexamethasone—psoriatic arthritis	0.00012	0.00148	CcSEcCtD
Sulindac—Discomfort—Betamethasone—psoriatic arthritis	0.00012	0.00148	CcSEcCtD
Sulindac—Hypotension—Methylprednisolone—psoriatic arthritis	0.000119	0.00148	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—psoriatic arthritis	0.000119	0.00147	CcSEcCtD
Sulindac—Vision blurred—Prednisone—psoriatic arthritis	0.000117	0.00145	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000117	0.00144	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000116	0.00144	CcSEcCtD
Sulindac—Oedema—Betamethasone—psoriatic arthritis	0.000116	0.00144	CcSEcCtD
Sulindac—Oedema—Dexamethasone—psoriatic arthritis	0.000116	0.00144	CcSEcCtD
Sulindac—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000116	0.00144	CcSEcCtD
Sulindac—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000116	0.00144	CcSEcCtD
Sulindac—Insomnia—Triamcinolone—psoriatic arthritis	0.000116	0.00143	CcSEcCtD
Sulindac—Insomnia—Methylprednisolone—psoriatic arthritis	0.000116	0.00143	CcSEcCtD
Sulindac—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Anaemia—Prednisone—psoriatic arthritis	0.000115	0.00142	CcSEcCtD
Sulindac—Shock—Betamethasone—psoriatic arthritis	0.000114	0.00141	CcSEcCtD
Sulindac—Shock—Dexamethasone—psoriatic arthritis	0.000114	0.00141	CcSEcCtD
Sulindac—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000114	0.00141	CcSEcCtD
Sulindac—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000114	0.00141	CcSEcCtD
Sulindac—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000114	0.00141	CcSEcCtD
Sulindac—Tachycardia—Dexamethasone—psoriatic arthritis	0.000113	0.0014	CcSEcCtD
Sulindac—Tachycardia—Betamethasone—psoriatic arthritis	0.000113	0.0014	CcSEcCtD
Sulindac—Angioedema—Prednisone—psoriatic arthritis	0.000113	0.0014	CcSEcCtD
Sulindac—CYP1A1—skin of body—psoriatic arthritis	0.000113	0.0313	CbGeAlD
Sulindac—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000113	0.00139	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000113	0.00139	CcSEcCtD
Sulindac—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000113	0.00139	CcSEcCtD
Sulindac—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000112	0.00139	CcSEcCtD
Sulindac—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000112	0.00139	CcSEcCtD
Sulindac—Malaise—Prednisone—psoriatic arthritis	0.000112	0.00138	CcSEcCtD
Sulindac—MAPK3—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000112	0.0139	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000112	0.0139	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000112	0.0139	CbGpPWpGaD
Sulindac—Vertigo—Prednisone—psoriatic arthritis	0.000111	0.00138	CcSEcCtD
Sulindac—Syncope—Prednisone—psoriatic arthritis	0.000111	0.00138	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—psoriatic arthritis	0.000111	0.00137	CcSEcCtD
Sulindac—Anorexia—Dexamethasone—psoriatic arthritis	0.000111	0.00137	CcSEcCtD
Sulindac—Anorexia—Betamethasone—psoriatic arthritis	0.000111	0.00137	CcSEcCtD
Sulindac—MAPK3—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000111	0.0138	CbGpPWpGaD
Sulindac—Urticaria—Prednisolone—psoriatic arthritis	0.000111	0.00137	CcSEcCtD
Sulindac—Fatigue—Triamcinolone—psoriatic arthritis	0.00011	0.00137	CcSEcCtD
Sulindac—Fatigue—Methylprednisolone—psoriatic arthritis	0.00011	0.00136	CcSEcCtD
Sulindac—Loss of consciousness—Prednisone—psoriatic arthritis	0.000109	0.00135	CcSEcCtD
Sulindac—MAPK3—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000109	0.0135	CbGpPWpGaD
Sulindac—Hypotension—Betamethasone—psoriatic arthritis	0.000109	0.00134	CcSEcCtD
Sulindac—Hypotension—Dexamethasone—psoriatic arthritis	0.000109	0.00134	CcSEcCtD
Sulindac—Convulsion—Prednisone—psoriatic arthritis	0.000107	0.00133	CcSEcCtD
Sulindac—Hypertension—Prednisone—psoriatic arthritis	0.000107	0.00132	CcSEcCtD
Sulindac—Chills—Methotrexate—psoriatic arthritis	0.000107	0.00132	CcSEcCtD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—TNF—psoriatic arthritis	0.000106	0.0132	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000106	0.00131	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000106	0.00131	CcSEcCtD
Sulindac—Myalgia—Prednisone—psoriatic arthritis	0.000106	0.00131	CcSEcCtD
Sulindac—Arthralgia—Prednisone—psoriatic arthritis	0.000106	0.00131	CcSEcCtD
Sulindac—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000106	0.00131	CcSEcCtD
Sulindac—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000105	0.0013	CcSEcCtD
Sulindac—Alopecia—Methotrexate—psoriatic arthritis	0.000105	0.0013	CcSEcCtD
Sulindac—Insomnia—Dexamethasone—psoriatic arthritis	0.000105	0.0013	CcSEcCtD
Sulindac—Insomnia—Betamethasone—psoriatic arthritis	0.000105	0.0013	CcSEcCtD
Sulindac—MAPK3—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000105	0.013	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000105	0.00129	CcSEcCtD
Sulindac—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000104	0.00129	CcSEcCtD
Sulindac—Paraesthesia—Betamethasone—psoriatic arthritis	0.000104	0.00129	CcSEcCtD
Sulindac—Discomfort—Prednisone—psoriatic arthritis	0.000104	0.00129	CcSEcCtD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000103	0.0128	CbGpPWpGaD
Sulindac—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000103	0.00127	CcSEcCtD
Sulindac—Dyspepsia—Betamethasone—psoriatic arthritis	0.000102	0.00127	CcSEcCtD
Sulindac—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000102	0.00127	CcSEcCtD
Sulindac—Urticaria—Triamcinolone—psoriatic arthritis	0.000102	0.00126	CcSEcCtD
Sulindac—Urticaria—Methylprednisolone—psoriatic arthritis	0.000102	0.00126	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—psoriatic arthritis	0.000102	0.00126	CcSEcCtD
Sulindac—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000101	0.00125	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000101	0.00125	CcSEcCtD
Sulindac—Oedema—Prednisone—psoriatic arthritis	0.000101	0.00125	CcSEcCtD
Sulindac—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000101	0.00125	CcSEcCtD
Sulindac—Decreased appetite—Betamethasone—psoriatic arthritis	0.000101	0.00125	CcSEcCtD
Sulindac—Fatigue—Betamethasone—psoriatic arthritis	0.0001	0.00124	CcSEcCtD
Sulindac—Fatigue—Dexamethasone—psoriatic arthritis	0.0001	0.00124	CcSEcCtD
Sulindac—Shock—Prednisone—psoriatic arthritis	9.96e-05	0.00123	CcSEcCtD
Sulindac—PTGS1—skin of body—psoriatic arthritis	9.96e-05	0.0275	CbGeAlD
Sulindac—MAPK3—MyD88-independent cascade—NOD2—psoriatic arthritis	9.9e-05	0.0123	CbGpPWpGaD
Sulindac—Tachycardia—Prednisone—psoriatic arthritis	9.88e-05	0.00122	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—psoriatic arthritis	9.79e-05	0.00121	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—psoriatic arthritis	9.77e-05	0.00121	CcSEcCtD
Sulindac—MAPK3—ATF-2 transcription factor network—NOS2—psoriatic arthritis	9.71e-05	0.0121	CbGpPWpGaD
Sulindac—Anorexia—Prednisone—psoriatic arthritis	9.65e-05	0.00119	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—psoriatic arthritis	9.62e-05	0.00119	CcSEcCtD
Sulindac—Anaemia—Methotrexate—psoriatic arthritis	9.58e-05	0.00118	CcSEcCtD
Sulindac—Feeling abnormal—Dexamethasone—psoriatic arthritis	9.58e-05	0.00118	CcSEcCtD
Sulindac—Feeling abnormal—Betamethasone—psoriatic arthritis	9.58e-05	0.00118	CcSEcCtD
Sulindac—PTGS2—skin of body—psoriatic arthritis	9.52e-05	0.0263	CbGeAlD
Sulindac—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	9.51e-05	0.00118	CcSEcCtD
Sulindac—Gastrointestinal pain—Betamethasone—psoriatic arthritis	9.51e-05	0.00118	CcSEcCtD
Sulindac—Hypersensitivity—Triamcinolone—psoriatic arthritis	9.44e-05	0.00117	CcSEcCtD
Sulindac—Hypersensitivity—Methylprednisolone—psoriatic arthritis	9.42e-05	0.00116	CcSEcCtD
Sulindac—Malaise—Methotrexate—psoriatic arthritis	9.35e-05	0.00116	CcSEcCtD
Sulindac—Vertigo—Methotrexate—psoriatic arthritis	9.31e-05	0.00115	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—psoriatic arthritis	9.28e-05	0.00115	CcSEcCtD
Sulindac—Urticaria—Dexamethasone—psoriatic arthritis	9.24e-05	0.00114	CcSEcCtD
Sulindac—Urticaria—Betamethasone—psoriatic arthritis	9.24e-05	0.00114	CcSEcCtD
Sulindac—MAPK3—Signaling by Interleukins—NOD2—psoriatic arthritis	9.23e-05	0.0115	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	9.22e-05	0.00114	CcSEcCtD
Sulindac—Dizziness—Prednisolone—psoriatic arthritis	9.21e-05	0.00114	CcSEcCtD
Sulindac—Asthenia—Triamcinolone—psoriatic arthritis	9.19e-05	0.00114	CcSEcCtD
Sulindac—Body temperature increased—Betamethasone—psoriatic arthritis	9.19e-05	0.00114	CcSEcCtD
Sulindac—Body temperature increased—Dexamethasone—psoriatic arthritis	9.19e-05	0.00114	CcSEcCtD
Sulindac—Asthenia—Methylprednisolone—psoriatic arthritis	9.17e-05	0.00113	CcSEcCtD
Sulindac—Insomnia—Prednisone—psoriatic arthritis	9.16e-05	0.00113	CcSEcCtD
Sulindac—Paraesthesia—Prednisone—psoriatic arthritis	9.09e-05	0.00112	CcSEcCtD
Sulindac—Pruritus—Triamcinolone—psoriatic arthritis	9.07e-05	0.00112	CcSEcCtD
Sulindac—Pruritus—Methylprednisolone—psoriatic arthritis	9.04e-05	0.00112	CcSEcCtD
Sulindac—Convulsion—Methotrexate—psoriatic arthritis	8.98e-05	0.00111	CcSEcCtD
Sulindac—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	8.94e-05	0.0111	CbGpPWpGaD
Sulindac—Dyspepsia—Prednisone—psoriatic arthritis	8.91e-05	0.0011	CcSEcCtD
Sulindac—MAPK3—Activated TLR4 signalling—NOD2—psoriatic arthritis	8.91e-05	0.0111	CbGpPWpGaD
Sulindac—MAPK3—AGE/RAGE pathway—NOS2—psoriatic arthritis	8.88e-05	0.011	CbGpPWpGaD
Sulindac—Myalgia—Methotrexate—psoriatic arthritis	8.83e-05	0.00109	CcSEcCtD
Sulindac—Chest pain—Methotrexate—psoriatic arthritis	8.83e-05	0.00109	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—psoriatic arthritis	8.83e-05	0.00109	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—psoriatic arthritis	8.8e-05	0.00109	CcSEcCtD
Sulindac—Rash—Prednisolone—psoriatic arthritis	8.78e-05	0.00109	CcSEcCtD
Sulindac—Dermatitis—Prednisolone—psoriatic arthritis	8.78e-05	0.00108	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-C—psoriatic arthritis	8.78e-05	0.0109	CbGpPWpGaD
Sulindac—MAPK3—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	8.77e-05	0.0109	CbGpPWpGaD
Sulindac—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	8.77e-05	0.0109	CbGpPWpGaD
Sulindac—Diarrhoea—Methylprednisolone—psoriatic arthritis	8.75e-05	0.00108	CcSEcCtD
Sulindac—Fatigue—Prednisone—psoriatic arthritis	8.73e-05	0.00108	CcSEcCtD
Sulindac—Headache—Prednisolone—psoriatic arthritis	8.73e-05	0.00108	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	8.72e-05	0.0108	CbGpPWpGaD
Sulindac—Discomfort—Methotrexate—psoriatic arthritis	8.72e-05	0.00108	CcSEcCtD
Sulindac—Constipation—Prednisone—psoriatic arthritis	8.66e-05	0.00107	CcSEcCtD
Sulindac—Dizziness—Triamcinolone—psoriatic arthritis	8.47e-05	0.00105	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—psoriatic arthritis	8.46e-05	0.00105	CcSEcCtD
Sulindac—MAPK3—DAP12 interactions—HLA-C—psoriatic arthritis	8.46e-05	0.0105	CbGpPWpGaD
Sulindac—Dizziness—Methylprednisolone—psoriatic arthritis	8.45e-05	0.00105	CcSEcCtD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	8.38e-05	0.0104	CbGpPWpGaD
Sulindac—Feeling abnormal—Prednisone—psoriatic arthritis	8.34e-05	0.00103	CcSEcCtD
Sulindac—Asthenia—Dexamethasone—psoriatic arthritis	8.34e-05	0.00103	CcSEcCtD
Sulindac—Asthenia—Betamethasone—psoriatic arthritis	8.34e-05	0.00103	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—psoriatic arthritis	8.28e-05	0.00102	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—psoriatic arthritis	8.28e-05	0.00102	CcSEcCtD
Sulindac—Nausea—Prednisolone—psoriatic arthritis	8.28e-05	0.00102	CcSEcCtD
Sulindac—Pruritus—Dexamethasone—psoriatic arthritis	8.23e-05	0.00102	CcSEcCtD
Sulindac—Pruritus—Betamethasone—psoriatic arthritis	8.23e-05	0.00102	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—psoriatic arthritis	8.18e-05	0.00101	CcSEcCtD
Sulindac—Vomiting—Triamcinolone—psoriatic arthritis	8.15e-05	0.00101	CcSEcCtD
Sulindac—Vomiting—Methylprednisolone—psoriatic arthritis	8.13e-05	0.001	CcSEcCtD
Sulindac—Rash—Triamcinolone—psoriatic arthritis	8.08e-05	0.000999	CcSEcCtD
Sulindac—Dermatitis—Triamcinolone—psoriatic arthritis	8.07e-05	0.000998	CcSEcCtD
Sulindac—Anorexia—Methotrexate—psoriatic arthritis	8.07e-05	0.000997	CcSEcCtD
Sulindac—Rash—Methylprednisolone—psoriatic arthritis	8.06e-05	0.000996	CcSEcCtD
Sulindac—Dermatitis—Methylprednisolone—psoriatic arthritis	8.05e-05	0.000996	CcSEcCtD
Sulindac—Urticaria—Prednisone—psoriatic arthritis	8.04e-05	0.000994	CcSEcCtD
Sulindac—Headache—Triamcinolone—psoriatic arthritis	8.03e-05	0.000992	CcSEcCtD
Sulindac—Headache—Methylprednisolone—psoriatic arthritis	8.01e-05	0.00099	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—psoriatic arthritis	8e-05	0.000989	CcSEcCtD
Sulindac—Diarrhoea—Betamethasone—psoriatic arthritis	7.95e-05	0.000983	CcSEcCtD
Sulindac—Diarrhoea—Dexamethasone—psoriatic arthritis	7.95e-05	0.000983	CcSEcCtD
Sulindac—Hypotension—Methotrexate—psoriatic arthritis	7.91e-05	0.000977	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	7.71e-05	0.000953	CcSEcCtD
Sulindac—Dizziness—Dexamethasone—psoriatic arthritis	7.69e-05	0.00095	CcSEcCtD
Sulindac—Dizziness—Betamethasone—psoriatic arthritis	7.69e-05	0.00095	CcSEcCtD
Sulindac—Insomnia—Methotrexate—psoriatic arthritis	7.65e-05	0.000946	CcSEcCtD
Sulindac—Nausea—Triamcinolone—psoriatic arthritis	7.61e-05	0.000941	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—psoriatic arthritis	7.6e-05	0.000939	CcSEcCtD
Sulindac—Nausea—Methylprednisolone—psoriatic arthritis	7.59e-05	0.000939	CcSEcCtD
Sulindac—PTGS1—tendon—psoriatic arthritis	7.58e-05	0.0209	CbGeAlD
Sulindac—Dyspnoea—Methotrexate—psoriatic arthritis	7.54e-05	0.000933	CcSEcCtD
Sulindac—Somnolence—Methotrexate—psoriatic arthritis	7.52e-05	0.00093	CcSEcCtD
Sulindac—MAPK3—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	7.46e-05	0.00926	CbGpPWpGaD
Sulindac—Hypersensitivity—Prednisone—psoriatic arthritis	7.46e-05	0.000922	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—psoriatic arthritis	7.45e-05	0.000921	CcSEcCtD
Sulindac—Vomiting—Betamethasone—psoriatic arthritis	7.39e-05	0.000914	CcSEcCtD
Sulindac—Vomiting—Dexamethasone—psoriatic arthritis	7.39e-05	0.000914	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—psoriatic arthritis	7.36e-05	0.000909	CcSEcCtD
Sulindac—Rash—Betamethasone—psoriatic arthritis	7.33e-05	0.000906	CcSEcCtD
Sulindac—Rash—Dexamethasone—psoriatic arthritis	7.33e-05	0.000906	CcSEcCtD
Sulindac—Dermatitis—Dexamethasone—psoriatic arthritis	7.32e-05	0.000905	CcSEcCtD
Sulindac—Dermatitis—Betamethasone—psoriatic arthritis	7.32e-05	0.000905	CcSEcCtD
Sulindac—Fatigue—Methotrexate—psoriatic arthritis	7.3e-05	0.000902	CcSEcCtD
Sulindac—Headache—Dexamethasone—psoriatic arthritis	7.28e-05	0.0009	CcSEcCtD
Sulindac—Headache—Betamethasone—psoriatic arthritis	7.28e-05	0.0009	CcSEcCtD
Sulindac—Asthenia—Prednisone—psoriatic arthritis	7.26e-05	0.000898	CcSEcCtD
Sulindac—PTGS2—tendon—psoriatic arthritis	7.24e-05	0.02	CbGeAlD
Sulindac—Pruritus—Prednisone—psoriatic arthritis	7.16e-05	0.000885	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	7.11e-05	0.00883	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	7.09e-05	0.00881	CbGpPWpGaD
Sulindac—Feeling abnormal—Methotrexate—psoriatic arthritis	6.97e-05	0.000862	CcSEcCtD
Sulindac—Diarrhoea—Prednisone—psoriatic arthritis	6.93e-05	0.000856	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—psoriatic arthritis	6.92e-05	0.000855	CcSEcCtD
Sulindac—Nausea—Dexamethasone—psoriatic arthritis	6.91e-05	0.000854	CcSEcCtD
Sulindac—Nausea—Betamethasone—psoriatic arthritis	6.91e-05	0.000854	CcSEcCtD
Sulindac—Urticaria—Methotrexate—psoriatic arthritis	6.72e-05	0.000831	CcSEcCtD
Sulindac—Dizziness—Prednisone—psoriatic arthritis	6.7e-05	0.000828	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—psoriatic arthritis	6.69e-05	0.000827	CcSEcCtD
Sulindac—Vomiting—Prednisone—psoriatic arthritis	6.44e-05	0.000796	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—MEFV—psoriatic arthritis	6.42e-05	0.00797	CbGpPWpGaD
Sulindac—Rash—Prednisone—psoriatic arthritis	6.38e-05	0.000789	CcSEcCtD
Sulindac—Dermatitis—Prednisone—psoriatic arthritis	6.38e-05	0.000788	CcSEcCtD
Sulindac—Headache—Prednisone—psoriatic arthritis	6.34e-05	0.000784	CcSEcCtD
Sulindac—MAPK3—TWEAK Signaling Pathway—TNF—psoriatic arthritis	6.32e-05	0.00785	CbGpPWpGaD
Sulindac—Hypersensitivity—Methotrexate—psoriatic arthritis	6.23e-05	0.000771	CcSEcCtD
Sulindac—Asthenia—Methotrexate—psoriatic arthritis	6.07e-05	0.00075	CcSEcCtD
Sulindac—Nausea—Prednisone—psoriatic arthritis	6.01e-05	0.000743	CcSEcCtD
Sulindac—Pruritus—Methotrexate—psoriatic arthritis	5.99e-05	0.00074	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	5.86e-05	0.00728	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	5.79e-05	0.00719	CbGpPWpGaD
Sulindac—Diarrhoea—Methotrexate—psoriatic arthritis	5.79e-05	0.000716	CcSEcCtD
Sulindac—ALB—Vitamin B12 Metabolism—CRP—psoriatic arthritis	5.76e-05	0.00715	CbGpPWpGaD
Sulindac—MAPK3—Ceramide signaling pathway—TNF—psoriatic arthritis	5.68e-05	0.00706	CbGpPWpGaD
Sulindac—Dizziness—Methotrexate—psoriatic arthritis	5.6e-05	0.000692	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—NOS2—psoriatic arthritis	5.58e-05	0.00692	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	5.5e-05	0.00683	CbGpPWpGaD
Sulindac—Vomiting—Methotrexate—psoriatic arthritis	5.38e-05	0.000665	CcSEcCtD
Sulindac—Rash—Methotrexate—psoriatic arthritis	5.34e-05	0.00066	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—psoriatic arthritis	5.33e-05	0.000659	CcSEcCtD
Sulindac—Headache—Methotrexate—psoriatic arthritis	5.3e-05	0.000655	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-B—psoriatic arthritis	5.19e-05	0.00644	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TNF—psoriatic arthritis	5.17e-05	0.00642	CbGpPWpGaD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	5.1e-05	0.00633	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—psoriatic arthritis	5.03e-05	0.000621	CcSEcCtD
Sulindac—PPARD—Adipogenesis—TNF—psoriatic arthritis	5.02e-05	0.00623	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HLA-B—psoriatic arthritis	5e-05	0.00621	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—CRP—psoriatic arthritis	4.68e-05	0.00581	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	4.6e-05	0.00571	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	4.41e-05	0.00547	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-DRB1—psoriatic arthritis	4.39e-05	0.00546	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	4.31e-05	0.00535	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—TNF—psoriatic arthritis	3.82e-05	0.00474	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MEFV—psoriatic arthritis	3.74e-05	0.00464	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—CRP—psoriatic arthritis	3.72e-05	0.00462	CbGpPWpGaD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	3.63e-05	0.00451	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	3.5e-05	0.00434	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	3.47e-05	0.0043	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	3.38e-05	0.00419	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	3.32e-05	0.00412	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-C—psoriatic arthritis	3.29e-05	0.00408	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	3.27e-05	0.00406	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	3.11e-05	0.00386	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	3.1e-05	0.00385	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	3.1e-05	0.00385	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	2.93e-05	0.00364	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TNF—psoriatic arthritis	2.77e-05	0.00344	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	2.62e-05	0.00326	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—psoriatic arthritis	2.61e-05	0.00324	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	2.43e-05	0.00301	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NOD2—psoriatic arthritis	2.42e-05	0.003	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TNF—psoriatic arthritis	2.12e-05	0.00263	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—psoriatic arthritis	2.09e-05	0.00259	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	2.08e-05	0.00258	CbGpPWpGaD
Sulindac—MAPK3—Immune System—REL—psoriatic arthritis	2.08e-05	0.00258	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	1.98e-05	0.00246	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	1.98e-05	0.00246	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-B—psoriatic arthritis	1.94e-05	0.00241	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-C—psoriatic arthritis	1.91e-05	0.00238	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	1.88e-05	0.00234	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NOS2—psoriatic arthritis	1.74e-05	0.00216	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CRP—psoriatic arthritis	1.72e-05	0.00213	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—psoriatic arthritis	1.68e-05	0.00209	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	1.65e-05	0.00204	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NOD2—psoriatic arthritis	1.41e-05	0.00175	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—psoriatic arthritis	1.13e-05	0.00141	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	1.12e-05	0.00139	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CRP—psoriatic arthritis	1e-05	0.00124	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DRB1—psoriatic arthritis	9.58e-06	0.00119	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—psoriatic arthritis	8.8e-06	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS2—psoriatic arthritis	8.42e-06	0.00105	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS2—psoriatic arthritis	8.37e-06	0.00104	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—psoriatic arthritis	5.01e-06	0.000622	CbGpPWpGaD
